Kornimate/medical-research-clean huggingface dataset:
atorvastatin for reduction of 28-day mortality in covid-19: rct

Conditions: Covid19; SARS-CoV2 Infection; COVID-19 Pneumonia

Summary: this randomized placebo-controlled double-blinded clinical trial aims to test the efficacy of administering atorvastatin 40 mg to hospitalized covid-19 patients for 28 days on the all-cause 28-day mortality.


Eligibility criteria:
inclusion criteria: * we will include adult patients (≥18 years old) with severe and critical covid19 admitted to the covid19 mansoura university isolation hospital. we will include patients who are pcr-confirmed, clinically or radiologically diagnosed with covid19. cases are defined as severe or critical according to the who definition (19); where critical cases have ards, or sepsis, septic shock or pulmonary embolism, acute coronary syndrome, or acute stroke, while severe cases have the clinical signs of severe pneumonia and spo2 \<90% on room air, or rr \<30 breaths/min without any critical criteria. exclusion criteria: * chronic statin use, serum creatine kinase (sr ck) \> 5 times the upper limit of normal (uln), serum transaminases \> 5 times uln, acute hepatic failure, chronic liver disease (child-pugh classification c), history of rhabdomyolysis or myopathies, severe renal impairment not receiving renal replacement therapy (estimated cr cl\< 30 ml\\min ), pregnant and lactating women, patients who are expected to die within 48 hours, or patients on chronic colchicine, cyclosporines, or ritonavir.

Keywords: atorvastatin randomized clinical trial
peri-implant conditions mimic periodontal conditions

Conditions: Peri-Implantitis; Peri-implant Mucositis; Peri-implant Health; Periodontitis; Gingivitis

Summary: except for patients with referred clinical bruxism and uncontrolled medical conditions, the study included 123 implants with implanted fixed prostheses that had lasted at least six months after functional prosthetic loading. in all implant patients, the health scale ranged from implants and natural teeth to plaque, gingival index, bleeding in the probe, mouth depth, loss of clinical attachment, and dental implants. the health and illness of the implants have been determined. patients were divided into three groups: peri-implantitis, peri-implant mucositis, and peri-implant health. inclusion criteria: * patients between the ages of 18- 70 * drugs that have a systemically healthy and controlled treatment situation * drivers who have implant-supported fixed prostheses that have been at least six months after functional prosthetic loading among these groups, it was checked whether periodontitis was seen in patients with peri-implantitis, gingivitis in patients with peri-implant mucositis, and whether healthy gums were seen in individuals with peri-implant health. to determine the health and disease status of individuals' implants, plaque index (silness loe 1964), gingival index (loe silness 1963), bleeding on probing (ainoma bay 1975), pocket depth measurements, and clinical attachment level were collected.


Eligibility criteria:
inclusion criteria: * patients between the ages of 18- 70 * drugs that have a systemically healthy and controlled treatment situation * drivers who have implant-supported fixed prostheses that have been at least six months after functional prosthetic loading exclusion criteria: * bruxism * uncontrolled medical conditions
a study to investigate effects of ocrelizumab treatment on neurofilament light chain (nfl) levels and participant satisfaction in participants with multiple sclerosis (ms)

Conditions: Multiple Sclerosis

Summary: the main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneous (sc) after 12 months using the therapy administration satisfaction questionnaire subcutaneous (tasq-sc).


Eligibility criteria:
inclusion criteria: * diagnosis of ms * rms and ppms participants diagnosed according to the mcdonald criteria of 2017 * first treatment during the course of ms therapy with ocrelizumab sc according to the local prescribing information, regardless of the reason for starting treatment with ocrelizumab exclusion criteria: * participation in interventional studies investigating dmts for ms * prior or simultaneous participation in confidence or moozart (isrctn55332718) non interventional study (nis) at the same study site * prior treatment with rituximab (mabthera®) or ublituximab (briumvi®) * severe psychiatric disability * pregnant and/or breastfeeding women
explorative trial evaluating the efficacy and tolerability of leo43204 in moderate to severe acne

Conditions: Acne Vulgaris

Summary: an exploratory phase 2, single, centre, prospective, randomized, placebo-controlled, double-blinded, split-pace (left/right) design trial to evaluate the efficacy and tolerability of leo 43204 in adults with moderate to severe acne.


Eligibility criteria:
inclusion criteria: * subjects should be diagnosed with acne vulgaris of the face * fitzpatrick skin types i-iii (due to lack of safety data for the investigational product in darker skin types) * disease severity and total lesion count should be similar in both tas * disease severity grade as moderate to severe according to the investigator's global assessment (grade 3-4) * age 18 to 35 years incl. * male or female * female subjects must be of either non-childbearing potential or child-bearing potential with a confirmed negative pregnancy test exclusion criteria: * subjects with nodulocystic acne, acne conglobata, acne fulminans, secondary acne (e.g. chlor-acne, drug-induced acne) * subjects with previous history of keloid formation or post-inflammatory hyperpigmentation * systemic retinoids within 12 month or systemic antibiotics within 1 month before day 1 * topical retinoids within 3 months before day 1 or other topical treatments and/or medicated products and cosmetics that in the opinion of the investigator may influence the subjects acne vulgaris (including soaps containing antibacterial agents such as benzoyl peroxide, keratinolytic agents such as salicylic acid, skin fresheners/astringents or aftershave products) within 1 month before day 1
comparison of thoracic epidural analgesia and intercostal blockade in patients undergoing thoracotomy

Conditions: Analgesia, Postoperative

Summary: postoperative pain is an important issue after thoracotomy operations. thoracic epidural analgesia is most popular analgesic method, but sometimes it is not sufficient for pain. this study is designed to compare intercostal block with thoracic epidural analgesia in patients undergoing thoracotomy


Eligibility criteria:
inclusion criteria: lung cancer exclusion criteria: patient refusal bleeding diathesisi emergency cases -
family-based health education program and zinc supplementation for stunted mother

Conditions: Stunting; Maternal-Fetal Relations

Summary: background : it is important to tackle the issue of malnutrition at an early stage. a stunted mother has a tendency of having adverse neonatal outcomes including growth restriction. the multidisciplinary intervention followed by micronutrient supplementation is developed to prevent these adverse outcomes. zinc has been associated with better neonatal growth and brain growth. this study aims to assess the impact of family-based health education programs plus zinc supplementation on the important biomarker of pregnancy and neonatal growth. objective : 1. to assess the impact of family-based health education programs plus zinc supplementation on the outcome of pregnancy in stunted mother 2. 1. to assess the impact of family-based health education programs plus zinc supplementation on the outcome of neonatal growth in stunted mother methodology : a quasi-experimental study involving stunted pregnant mother with parallel intervention hypothesis : mother who receives the intervention will have the better maternal and neonatal outcome

details of family-based health education program + zinc : 1. home-visit and health promotion by trained midwives 2. supervision by health volunteer 3. zinc supplementation general target population : 1. stunted pregnant mother on the third trimester of pregnancy 2. conducted in primary health care center design of study : two arms quasi-experimental study with one group receiving the intervention and comparison receiving standard antenatal care. the baseline measurement is conducted at the beginning of the third trimester, followed by the day of delivery and 6 months after delivery (for assessing the outcome of the infant). participants are matched by certain variables variable : 1. sociodemographic information 2. food recall using food frequency questionnaire list of outcomes 1. zinc level in breastmilk and blood of mother and infant 2. insulin-like growth factor 1 (igf-1) level of mother and infant 3. hemoglobin level of mother and infant 4. infant and placental anthropometry 5. tumor growth factor beta 1 (tgf beta 1) in infant 6. brain-derived neurotrophic factor (bdnf) in infant sample size using the difference between two means of neonatal birth weight who received zinc and did not receive zinc according to a study in iran 1. type 1 error 5% 2. effect size: 0.4486 3. power of study: 80% 4. with the equal allocation ratio, the total sample needed is 126 proposed statistical analysis 1. independent t-test 2. linear mixed model

Eligibility criteria:
inclusion criteria 1. body height is less than 150 cm 2. upper arm circumference less than 23.5 cm 3. family income is less than rp 2,500,000,- following the minimum wage of targeted area 4. 24-26 weeks pregnant. exclusion criteria 1. has pregnancy complications 2. multiple infants 3. refuse to follow the protocol

Keywords: insulin-like growth factor 1 zinc hemoglobin health education stunting low-income family
effect of magnesium sulphate on the intracranial pressure of preeclamptic patients

Conditions: Preeclampsia Severe

Summary: it had been shown that high percentage of severe preeclampsia patients got a high cerebral perfusion pressure (cpp) due to abnormal autoregulation of cerebral blood vessels with associated endothelial dysfunction and disrupted blood brain barrier. moreover, patients with high cpp is more likely to present with headache compared to other patients with normal cpp.in this particular scenario, use of magnesium sulphate is associated with marked reduction of cpp and. hence prevention of cerebral damage.this hypothesis was confirmed by new magnetic resonance techniques that demonstrated brain edema in eclampsia/ severe preeclampsia patient mostly due to vasogenic edema and less commonly attributed to cytotoxic edema. changes in the optic nerve sheath diameter (onsd) mirrors the changes in the intracranial pressure(icp), subsequently when the intracranial pressure increases the optic nerve sheath diameter (onds) also increases. the aim of this study is to determine the effect magnesium sulphate infusion on intracranial pressure, in patients presented with severe preeclampsia by measuring changes in the onsd using ultrasound examination.

30 obstetric patients admitted to the hdu in corniche hospital for treatment of severe preeclampsia. patients with the following criteria will be excluded from the current work: patients undergone cranial or eye surgeries, patients with known intracranial pathology, patients suffering from glaucoma or any other eye pathology that prevent clear identification of the optic nerve, and patients on drugs that may affect the cerebrospinal fluid \[based on operator decision\]. in this prospective pilot study, patients who will fulfill the inclusion criteria will be recruited at the time of admission in hdu by the investigators. the onds will be measured before the commencement of magnesium sulphate infusion, 1hr after finishing the loading dose, 6 and 24 hrs after infusion started. patients will be in supine position with the head of the bed less than 20 degrees. high frequency (7.5 mhz) linear probe will be used; it will be placed gently over both closed eye after liberal application of sterile gel, the patient will be instructed to look forward to align the optic nerve directly opposite to the probe. the onsd will be measured 3mm behind the optic disc in both the sagittal and transverse planes and an average will be calculated and recorded. in the absence of complete visualization of the optic disc, the largest viewed diameter will be taken as the maximal onsd. hemodynamic variables \& oxygen saturation will be recorded at the same times.

Eligibility criteria:
inclusion criteria: * obstetric patients admitted to the hdu at corniche hospital for treatment of severe preeclampsia exclusion criteria: * (1) patients undergone cranial or eye surgeries, (2) patients with known intracranial pathology, (3) patients suffering from glaucoma or any other eye pathology that prevent clear identification of the optic nerve, (4) patients on drugs that may affect the cerebrospinal fluid
centrimag ventricular assist system in treating failure-to-wean from cardiopulmonary bypass for pediatric patients

Conditions: Heart Failure

Summary: the purpose of the study is to evaluate the safety and effectiveness of the centrimag ventricular assist system to help pediatric patients who have experienced heart failure during surgery and cannot be removed from cardiac bypass.


Eligibility criteria:
inclusion criteria: 1. age 5 years to 16 years, inclusive 2. inability to wean from cardiopulmonary bypass (cpb) exclusion criteria: 1. body weight \< 20 kg 2. severe aortic insufficiency 3. unrestricted intra-cardiac communications (i.e. large vsd) 4. pulmonary vascular resistance index (pvri) \> 10 iu 5. presence of dic 6. on hemodialysis (excluding hemofiltration) 7. contraindications to systemic anticoagulation 8. active systemic infection unresponsive to antibiotics 9. unresolved malignancy 10. on other investigational vas

Keywords: thoratec corporation
clinical study of impact of different pacing site in patients

Conditions: Bradyarrhythmias; Heart Failure; Pacemaker

Summary: at present, cardiac pacing has been widely used in the treatment of bradyarrhythmias and heart failure, which can effectively improve the survival rate of patients. with the rapid development of technology, different sites can be chosen to pace, such as right atrial appendage, the atrial septum and the right atrial wall in the atrium, his bundle, left bundle branch area, right ventricular apex, outflow tract, and left ventricular pacing via coronary vein in the ventricle. there are few studies comparing the long-term efficacy and safety of different pacing sites in daily practice. this study aims to observe the efficacy and safety of cardiac pacing at different sites in short and long term, and to compare the advantages and disadvantages of pacing at different sites.


Eligibility criteria:
inclusion criteria: * patients who received pacemaker implantation in the second hospital of zhejiang medical university by pan xiaohong and other surgeons. * patients who have the ability to understand the test and can cooperate with investigators. exclusion criteria: * patients who unable to understand or unwilling to fill in informed consent forms or follow visitors.
garlic in hyperlipidemia caused by haart

Conditions: HIV Infections; Hypercholesterolemia; Hypertriglyceridemia; Hyperglycemia

Summary: the purpose of this study is to test the effectiveness and tolerability of garlic pills in lowering cholesterol and triglycerides in hyperlipidemic hiv-infected individuals who are being treated with highly active antiretroviral therapy (haart).

clinical evaluation of garlic in hiv disease is warranted for several reasons. first, garlic is used as a botanical medicine and as an alternative therapy by many hiv-infected individuals. baseline data from the bastyr's alternative medicine care outcomes in aids (amcoa) study \[1\] indicate that garlic is the most frequently used botanical medicine among hiv-infected men and women (52.9%) who utilize complementary and alternative medicine (cam). in the same cohort, 50% of the subjects who use antiretroviral therapy are also taking garlic supplements. second, there is a growing body of studies that indicate that garlic exhibits lipid and glucose lowering as well as hepato-protective activities. third, several of the pharmacological activities of garlic and their reported clinical benefits in other conditions, especially in hyperlipidemia, may be relevant in the management of highly active antiretroviral therapy (haart) in hiv-infected subjects. study medication: we will utilize garlicintm, an allicin-standardized dried garlic supplement in two escalating doses in hiv-infected subjects who are receiving haart.

Eligibility criteria:
inclusion criteria: * hiv-1 seropositive confirmed by medical history * on stable haart for at least 6 months before study entry without the likelihood of haart therapy changes in the following 6 months due to viral rebound or adverse events * cd4+ lymphocyte number \> 100 cells/mm3 measured within 60 days before study entry * hiv-1 viral load \< 2000 rna copies/ml * cholesterol \> 200 mg/dl * triglycerides \> 250 mg/dl \< 1000 mg/dl * willing and able to avoid raw or dry garlic, onion, leeks and shallots as well as supplements containing garlic during the 16 weeks of the trial * willing and able to provide inform consent * willing and able to understand and follow protocol for the duration of the study * willing and able to maintain a consistent lifestyle routine, eg. diet, exercise, medications, dietary supplements and sleep schedule for the duration of the study * willing and able to understand and follow the step 1 guidelines from the national cholesterol education program (ncep) for the duration of the study * willing to remain adherent to the current haart regimen

Keywords: complementary therapies garlic allium sativum metabolic diseases haart protease inhibitors
the effects of tegaserod vs. placebo on whole gut transit time in patients with chronic constipation and dyspepsia

Conditions: Constipation and Dyspepsia

Summary: to demonstrate the effects of tegaserod on gastrointestinal scintigraphic orocecal transit in female patients with cc and upper gi symptoms of dyspepsia


Eligibility criteria:
inclusion criteria: * females aged 18 to 64 years of age * patients must present with two or more of the following criteria for chronic constipation for at least 12 weeks prior to entering the study: 1. less than 3 bowel movements per week 2. hard or lumpy stools 3. straining during bowel movements 4. feeling of incomplete evacuation * patients must report overlapping symptoms consistent with dyspepsia, such as mid-upper abdominal discomfort characterized by early satiety, post-meal fullness and bloating exclusion criteria: * patients with a recent history of, or current frequency of diarrhea occuring more than once per month off of laxatives * clinically significant diagnosis of pelvic outlet obstruction or pelvic floor dyssenergia as determined by the study physicians * patients with constipation secondary to medication use as determined by the study physician * patients with clinically significant abnormal tsh levels at screening * patients that have heartburn or abdominal pain as their predominant gi symptom * evidence of cathartic colon or a history of laxative abuse * other protocol-defined inclusion/exclusion criteria may apply

Keywords: constipation, tegaserod, dyspepsia
strengthening exercises for fibromyalgia

Conditions: Fibromyalgia

Summary: objective: we evaluated the effectiveness of strengthening exercises using the swiss ball in patients with fibromyalgia (fm). material and method: sixty fm patients were randomized into two groups: an intervention group (ig), in which patients performed muscle strength exercises using the swiss ball, and a stretching group (sg), in which patients performed stretching exercises. all patients participated in 40-minute training sessions three times per week for 12 weeks. the ig performed the following eight strengthening exercises using a swiss ball: lateral rise, simultaneous biceps curl, squat, two arms triceps extension, abdominal, one arm dumbbell row, reverse crucifix and crucifix. the sg performed exercises targeting the same muscle groups trained in ig. outcome measures were as follows: visual analogue scale (vas) for pain, 1 repetition maximum test for muscle strength; fibromyalgia impact questionnaire (fiq) to evaluate disease impact, and short form health survey (sf-36) to assess quality of life. all participants underwent an evaluation at baseline, at 6 weeks and at 12 weeks of training. the assessor was blind to patient allocation.


Eligibility criteria:
inclusion criteria: * female with fibromyalgia according to the classification criteria of the american college of rheumatology; * aged between 20 and 65 years old. exclusion criteria: * uncontrolled hypertension; * decompensated cardiac disease; * history of syncope or exercise-induced arrhythmias and decompensated diabetes; * severe psychiatric illness; * history of regular exercise at least twice a week for the last 6 months; * any other condition that could prevent the patient from performing physical exercises.

Keywords: fibromyalgia muscle strength exercises pain quality of life
optimal dose of incisional local infiltration betamethasone for the prevention of pain after spinal surgery

Conditions: Pain Management; Spine Surgery

Summary: incisional pain is a common complication after surgery and is an important cause of delayed postoperative recovery, increased length of hospital stay, increased risk of wound infection and respiratory/cardiovascular complications, as well as an important medical, social, and economic problem. prevention and treatment of postoperative incision pain remains challenging. local infiltration anaesthesia (lia) for surgical incisions with an anti-inflammatory and analgesic combination has been reported to be effective in reducing postoperative pain, but there is a gap in the research on the optimal concentration of anti-inflammatory drugs in the anti-inflammatory and analgesic combination during local infiltration. the aim of this study was to investigate the optimal concentration of anti-inflammatory drugs in the anti-inflammatory-analgesic combination solution used for local infiltration of spinal surgical incisions to prevent postoperative pain.


Eligibility criteria:
inclusion criteria: patients scheduled for spine surgery under general anesthesia. anticipated cervical, thoracic, and lumbar spine surgeries (within three level). patients age 18-65 years. american society of anaesthesiologists classification of i or ii. exclusion criteria: patients refuse to participate. patients who are allergic to ropivacaine, betamethasone and opioid, . pateints who have been abusing drugs or alcohol. patients who have abnormalities in kidney or liver function tests. bmi\ 35 kg/m2. patient has a history of spinal surgery. patient has peri-incisional infection. patient has a history of stroke or other serious neurological disease. patient has a history of diabetes and other metabolic disorders. patient has a history of psychological disorders. patient is on systemic steroids. patient is pregnant or breastfeeding. glasgow coma scale score \< 15 before surgery. unable to provide written informed consent. withdrawal criteria: voluntary withdrawal. delayed extubation. poor cognitive function within 48 hours after surgery. postoperative radiation therapy or chemotherapy during follow-up. postoperative diagnosis of spinal cord or nerve root injury resulting in pain during follow-up. reoperation during follow-up.